CellaVision

118.40 SEK

-1.66%

1,477 following

CEVI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for CellaVision

2019202020212022202320242025
Revenue461.8471.4565.6639.3677.3723.2759.0
growth-%2.1 %20.0 %13.0 %5.9 %6.8 %4.9 %
EBITDA146.7142.9196.2198.0207.0219.0241.4
EBIT126.6110.3162.7158.3167.1177.7202.1
Profit before taxes129.2112.2158.3148.4164.2176.9194.3
Net income99.289.5125.3118.3130.3140.7153.1
EPS4.163.755.254.965.465.906.42
Dividend0.000.752.002.002.252.502.75
Dividend ratio0.0 %20.0 %38.1 %40.3 %41.2 %42.4 %42.8 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%31.8 %30.3 %34.7 %31.0 %30.6 %30.3 %31.8 %
EBIT-%27.4 %23.4 %28.8 %24.8 %24.7 %24.6 %26.6 %
ROE28.5 %20.8 %23.1 %18.4 %18.2 %17.3 %17.2 %
ROI15.5 %13.4 %15.2 %13.3 %14.0 %13.9 %14.0 %